Inocras raised $31 million in a Series B-3 round to expand its whole-genome sequencing platform and US commercial operations. Existing investors DSC Investment, Dunamu and Partners, and InterVest participated, joined by multiple new investors including IMM Investment and LoftyRock Investment. The company plans to use proceeds to scale its proprietary bioinformatics platform and grow its commercial and operational capacity. Inocras markets whole-genome sequencing diagnostic tests for solid tumors (CancerVision) and rare diseases (RareVision), and the company says its testing is already used across more than 100 cancer institutions in Asia. Inocras CEO Jehee Suh said the company’s objective is to bring clinical experience from its current footprint—including Hong Kong and South Korea—to the U.S., where it aims to support adoption of whole-genome analysis as part of cancer care.